iTeos Pharma (ITOS) - Long-Term Debt to Capital Coefficient
iTeos Therapeutics (ITOS) is implementing robotic systems to accelerate antibody selection in oncology, relieving scientists of repetitive tasks. This daily price chart on the GURU.Markets platform currently reflects a level of 0.01. The business's success relies on partnerships with industry behemoths and the availability of funds for final testing. The company operates in the growing tumor-fighting segment, where medical demand remains consistently high.
%20Long-Term%20Debt%20to%20Capital&width=1200&height=400&colorIndex=0&v=mvujvhid.si-7ayy9s0&start=20220704&end=20261030&filename=GURU_Markets_-_ITOS_-_iTeos-Therapeutics_-_Long-Term-Debt-to-Capital "ITOS: iTeos Therapeutics, Inc. Long-Term Debt to Capital 07/04/2022 - 09/14/2025 | 👁️GURU.Markets👁️")
Comprehensive metric breakdowns and analytics for iTeos Therapeutics (ITOS)
- stock price and consensus target price:
- market capitalization indicators:
- balance sheet net asset value indicators:
- debt and solvency information:
Total Debt to Equity Ratio iTeos Therapeutics|ITOS - Long-Term Debt to Capital|Short-Term Debt to Capital iteostherapeutics.com|ITOS - Company Total Debt|Debt to Net Assets Ratio iTeos Therapeutics, Inc.|ITOS - Company Long-Term Debts|Short-Term Debt Volume iTeos Therapeutics|Quick Liquidity Indicator iteostherapeutics.com
- net income and valuation ratios data:
General company analysis:iTeos Therapeutics Inc - ITOS
The stability of iTeos Therapeutics (ITOS) relies on the trust of the oncology community and the support of a global pharmaceutical partner. This long-term financial debt sustainability metric measures the proportion of liabilities exceeding one year relative to equity. An increase in the ratio signals a growing debt load on the asset structure. A downward trend in the curve confirms the autonomy of research and development funding. This allows for an objective assessment of the company's investment attractiveness and fair value.
Key competitors
argenx N.V. - Long-Term Liabilities to Equity|Long-Term Debt to Capital BNTX|ABVX (Abivax S.A.) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital ADMA (ADMA Biologics)|Long-Term Debt to Capital protagonist-inc.com PTGX|IMVT - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient KNSA (Kiniksa Pharmaceuticals, Ltd.)|Grifols Group (GRFS) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Adaptive Biotechnologies Inc.|CLDX (Celldex Therapeutics) - Long-Term Debt to Capital|Long-Term Debt to Capital auriniapharma.com|Long-Term Debt to Equity Ratio BCRX (BioCryst Pharmaceuticals)|VERA (Vera Therapeutics Inc) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital DNTH (Dianthus Pharma)|Ratio of Long-Term Indebtedness to Capital Pharvaris Pharma (PHVS)|ABCL - Long-Term Debt to Equity|tourmalinebio.com (TRML) - Long-Term Debt to Equity Ratio|Precigen (PGEN) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Pharming Group NV|Long-Term Debt to Equity Ratio NKTR|Long-Term Debt to Capital Upstream Pharma|Long-Term Debt to Equity Zenas Biopharma Inc (ZBIO)|immunome.com - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital GOSS (Gossamer Bio)|KalVista Pharma (KALV) - Long-Term Liabilities to Capital|Septerna Corp - Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital Pieris Corp PVLA|SVRA (Savara Inc.) - Long-Term Debt to Equity Ratio|RIGL: Long-Term Loans to Capital Ratio|ANAB (AnaptysBio) - Long-Term Debt to Capital|Long-Term Liabilities to Capital Astria Therapeutics Inc ATXS|Long-Term Debt to Equity enGene Bio (ENGN)|RAPT - Long-Term Liabilities to Capital|Long-Term Debt to Equity Aerovate Therapeutics JBIO|Ratio of Long-Term Indebtedness to Capital aclaristx.com (ACRS)|KYTX: Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient TLSA (Tiziana Life Sciences Ltd.)|CABA (Cabaletta Bio, Inc) - Long-Term Debt to Equity Ratio|VTYX: Long-Term Loans to Capital Ratio|THTX (Theratechnologies Inc.) - Long-Term Debt to Capital|AVTX: Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital ELDN|AGEN - Long-Term Liabilities to Capital|Long-Term Debt to Equity Climb Bio, Inc. CLYM|Long-Term Debt to Capital Coefficient ZURA|aTyr Pharma, Inc. - Long-Term Debt to Capital|ADAG - Long-Term Debt to Capital|ikenaoncology.com (IMA) - Long-Term Debt to Equity|Long-Term Liabilities to Equity STTK (Shattuck Labs)|EQ (Equillium Inc) - Long-Term Debt to Capital|Long-Term Liabilities to Capital Connect Pharma CNTB|Long-Term Debt to Equity Ratio IMUX (Immunic, Inc.)|Long-Term Debt to Capital atarabio.com (ATRA)|InflaRx - Long-Term Debt to Equity Ratio|Long-Term Loans to Capital Ratio XFOR (X4 Pharmaceuticals Inc.)|Adicet - Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital Celularity Inc. CELU|INMB: Long-Term Debt to Capital|Long-Term Debt to Equity Ratio barinthusbio.com|Long-Term Debt to Equity Kezar Life Sciences, Inc.|SAB Biotherapeutics Inc. (SABS) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Capital AKTX|Ratio of Long-Term Indebtedness to Capital enlivex.com|Q32 Bio - Long-Term Debt to Equity Ratio|Long-Term Loans to Capital Ratio GOVX (geovax.com)|EDSA - Long-Term Debt to Equity|Long-Term Liabilities to Capital iBio Inc|carismatx.com (CARM) - Long-Term Debt to Equity|XTLB - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Bolt Biotherapeutics Inc.|HCW Biologics Inc - Long-Term Liabilities to Equity|Long-Term Debt to Capital APVO|AIM (aimimmuno.com) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital ADTX (Aditxt, Inc.)|Long-Term Debt to Capital GRI Bio Corporation GRI|XRTX - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient HIND (reshapelifesciences.com)|Revelation Biosciences, Inc. (REVB) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Indaptus Therapeutics Inc|SCNI (Scinai) - Long-Term Debt to Capital|Long-Term Debt to Capital CalciMedica Corp|Long-Term Debt to Equity Ratio AFMD (Affimed)|ALLK (allakos.com) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital HOOK (HOOKIPA Pharma)|Ratio of Long-Term Indebtedness to Capital IGM Biosciences Inc. (IGMS)|OCEA - Long-Term Debt to Equity|TC BioPharm Ltd (TCBP) - Long-Term Debt to Equity Ratio|Third Harmonic Bio (THRD) - Long-Term Debt to Equity